Shandong Weigao Blood Purification Products Co (SHSE:603014) Research & Development: ¥151 Mil (TTM As of Mar. 2026)


SHSE:603014 Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
38 GF Score
Price ¥35.98
! 2 Warning Signs
View Full Analysis

What is Shandong Weigao Blood Purification Products Co Research & Development?

Shandong Weigao Blood Purification Products Co SHSE:603014 +2.36% 38 Research & Development is ¥151 Mil as of Mar. 2026. GuruFocus rates SHSE:603014 with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Shandong Weigao Blood Purification Products Co's Research & Development for the three months ended in Mar. 2026 was ¥38 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥151 Mil.

Shandong Weigao Blood Purification Products Co  (SHSE:603014) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Shandong Weigao Blood Purification Products Co Research & Development Related Terms

Shandong Weigao Blood Purification Products Co Research & Development Historical Data

* Premium members only.

The historical data trend for Shandong Weigao Blood Purification Products Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Weigao Blood Purification Products Co Research & Development Chart

Shandong Weigao Blood Purification Products Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 153.49 182.84 154.86 164.70 143.86

Shandong Weigao Blood Purification Products Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.44 39.74 35.53 38.16 37.54
SHSE:603014
38GF Score
Shandong Weigao Blood Purification Products Co Ltd SHSE:603014
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Weigao Blood Purification Products Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥151 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥151 Mil mean?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a Research & Development of ¥151 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Shandong Weigao Blood Purification Products Co and its competitors.
Is Shandong Weigao Blood Purification Products Co's Research & Development too high?
Shandong Weigao Blood Purification Products Co's current Research & Development is ¥151 Mil. Overall, Shandong Weigao Blood Purification Products Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Weigao Blood Purification Products Co's Research & Development compare to ABT and SYK?
Shandong Weigao Blood Purification Products Co's Research & Development of ¥151 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Shandong Weigao Blood Purification Products Co and its competitors. Shandong Weigao Blood Purification Products Co's current Research & Development is ¥151 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Weigao Blood Purification Products Co stock overvalued right now?
Shandong Weigao Blood Purification Products Co (SHSE:603014) has a current Research & Development of ¥151 Mil. The current Research & Development is ¥151 Mil. Shandong Weigao Blood Purification Products Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Shandong Weigao Blood Purification Products Co (SHSE:603014), the current Research & Development is ¥151 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shandong Weigao Blood Purification Products Co Business Description

Address No. 7, Weigao West Road, Torch High-tech Industrial Development Zone, Shandong Province, Weihai, CHN, 264200
Shandong Weigao Blood Purification Products Co Ltd engaged in research and development, production and sales of blood purification medical products.
38GF Score

Get the complete analysis for SHSE:603014

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥35.98
Price